chordoma/tyrosine

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 40 rezilta yo

Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are rare neoplasms arising from notochord remnants. Tyrosine kinase receptors (RTK) are altered in these lesions. We used a tissue microarray containing 58 chordomas to examine the expression of platelet-derived growth factor receptor (PDGFR)-α and PDGFR-β, epidermal growth factor receptor

Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Currently, there are no effective chemotherapeutic protocols for chordoma. Reports of receptor tyrosine kinase (RTK) expression in chordoma suggest that these tumours may respond to kinase inhibitor therapy. However, RTK signalling activity has not been extensively investigated in

Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are rare, locally aggressive malignancies that often exhibit an insidious natural history and are difficult to eradicate. Surgery and radiotherapy are the treatment mainstays of chordoma, but the chance of local recurrence remains high. Reports of receptor tyrosine kinase (RTK) expression

Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The aberrant activation of developmental processes triggers diverse cancer types. Chordoma is a rare, aggressive tumor arising from transformed notochord remnants. Several potentially oncogenic factors have been found to be deregulated in chordoma, yet causation remains uncertain. In particular,

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We have previously demonstrated that chordomas express activated platelet-derived growth factor receptor (PDGFRB) and that treatment with imatinib, which is capable of switching off the activation of various receptor tyrosine kinases (RTKs) including PDGFRB, benefits a number of patients. The aim of

Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are rare neoplasms arising along the axial skeleton. Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, evidence on the efficacy of Imatinib mesylate in

Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

While hypothyroidism has frequently been reported with the use of TKIs, the thyroid-stimulating hormone (TSH) suppressing effect of TKIs is rare, except for thyroiditis. We describe a case with progressive recurrent chordoma who initially became hyperthyroid in a context of autoimmunity under

[Novel molecular aspects of chordomas].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are rare and slowly growing malignant bone tumors which mostly occur in adults. These bone tumors are characterized by epithelial and mesenchymal aspects. It is suggested that they arise from remnants of the notochord because they are found along the axial skeleton (e.g. clival, spinal and

Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Currently there is no effective chemotherapy for chordoma. Recent studies report co-expression of insulin-like growth factor-1 receptor (IGF1R) and its cognate ligand in chordoma, but it is unknown whether this receptor tyrosine kinase is activated in these tumours. Additionally, genetic studies

Multidisciplinary approach of lumbo-sacral chordoma: From oncological treatment to reconstructive surgery.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lumbo-sacral chordoma is a rare, slow-growing tumor, arising from embryonic nothocordal remnants. Wide en bloc excision with clear margins remains mandatory to achieve satisfactory recurrence rates and disease-free survival. No chemotherapy has been demonstrated to be effective and radiotherapy is

The role of extracellular factors in human metastatic chordoma cell growth in vitro.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

METHODS Human metastatic chordoma cells were isolated, and initial in vitro characterization was performed. Biochemical and physiologic changes were observed in response to pH, oxygen, and glucose. OBJECTIVE The extracellular microenvironment directly affects metastatic chordoma cell phenotype in

Response to erlotinib in a patient with treatment refractory chordoma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are rare tumors arising from the axial skeleton. The disease is characterized by slow local growth, frequent local recurrences, and rare systemic spread. Surgery and local radiation remains the mainstay of treatment with minimal role of systemic therapy. Imatinib has been shown to be

Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

UNASSIGNED Adult sarcomas, especially those with metastatic or unresectable disease, have limited treatment options. Traditional chemotherapeutic options have been limited by poor response rates in patients with advanced sarcomas. The important clinical question is whether the success of targeted

Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are locally invasive tumors that have a tendency to relapse despite optimal treatment. Specific biological markers might be used to describe their behavior. There is currently no agreement regarding the best way to manage intracranial chordomas. We studied the expression of vascular

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chordomas are rare, slowly growing tumors with high medical need, arising in the axial skeleton from notochord remnants. The transcription factor "brachyury" represents a distinctive molecular marker and a key oncogenic driver of chordomas. Tyrosine kinase receptors are also expressed, but so far

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye